About
An educational reference, not a marketplace
Nootropic Peptides is an independent educational reference site covering research peptides relevant to cognitive enhancement, neuroprotection, mood, focus, and brain health. The site catalogues mechanism of action, published research, safety profile, and UK and EU regulatory status for each compound — written in a neutral, evidence-based tone, without therapeutic claims and without selling anything.
The peptides discussed here are research chemicals, not medicines. None are licensed for human use in the United Kingdom. The site exists because the existing online information landscape for these compounds is dominated by either marketing copy or speculation, and a neutral reference is genuinely useful for researchers, students, and informed readers who want to understand the actual state of the published literature.
Where the site links to commercial suppliers — explicitly, on each peptide page — it does so because researchers genuinely do need to source these compounds for laboratory work, and a clear pointer to known UK suppliers is more useful than pretending the question does not arise. Those links should be read as research-sourcing references, not as endorsements of human consumption.
How the site is structured
Each peptide profile follows the same template — quick-facts panel, biochemistry overview, discovery history, mechanism of action, researched benefits, theoretical dosing protocols, administration routes, safety profile, UK and EU regulatory context, clinical studies summary, FAQs, sourcing notes, and related peptides. The uniform structure means readers can compare across peptides quickly and can rely on finding the same kind of information in the same place.
Comparison pages, stack guides, and topic-level research summaries cover the cross-cutting questions — how does Semax differ from Selank, what does the BDNF-induction literature actually show, why is intranasal delivery the standard route in this research family.
Editorial process and update cadence
Every peptide profile carries a "last reviewed" date in its header. The default cadence is a quarterly audit — published research is checked, new studies are summarised, regulatory-status statements are reverified against current MHRA and EMA positions, and the last-reviewed date is bumped. High-profile updates (new clinical trial results, material regulatory changes, retractions in the literature) trigger immediate revisions outside the regular cadence.
We deliberately avoid auto-generated content and avoid republishing copy from supplier sites. Every page on this site is written from primary or peer-reviewed secondary sources by a human editor with the brief: write it as if the reader is a PhD student in pharmacology rather than a consumer.
Conflicts of interest and disclosure
This site links externally to two commercial peptide suppliers — PeptideAuthority.co.uk and PeptideBarn.co.uk — under "Sourcing for laboratory research" sections on each peptide page. Those links are not paid advertising and do not currently carry an affiliate commission. They are present because researchers do need a real-world answer to the "where do I get this for laboratory work" question, and named UK suppliers with traceable documentation are a meaningfully better answer than unverified offshore vendors.
If the commercial relationship changes — for instance, if these links become affiliate links — that disclosure will be added to every page that contains them. No content decision on this site (which peptides to cover, what to say about them, which studies to summarise) is influenced by any commercial relationship.
We do measure how often the supplier links are clicked. Clicks pass through an internal redirect that records the supplier, the source peptide page, the browser family, and a daily-salted hash of the visitor's IP address (the raw IP is not stored). This lets us see which peptide pages drive research-sourcing interest without tracking individual visitors across the site. Outbound supplier links carry rel="sponsored nofollow" in line with Google's guidance on sponsored or commercially relevant links, even though our supplier links are not currently paid placements. Full detail in the privacy policy.
Reporting errors
If you spot a factual error — a misstated mechanism, a study referenced incorrectly, a regulatory claim that is out of date — please flag it. Corrections are made within a working week and the affected page's "last reviewed" date is bumped. We treat corrections as a feature of the site, not an embarrassment: the only way to maintain a credible reference is to fix the things that turn out to be wrong.
Editorial masthead
Who writes and reviews this site
Nootropic Peptides Editorial Team — the writers and reviewers behind every peptide profile on the site. The team's core competencies cover research-peptide pharmacology, the Russian- and Soviet-era neuropeptide literature (Semax, Selank, Noopept, the Khavinson bioregulator canon), blood-brain-barrier peptide delivery, BDNF/NGF neurotrophin signalling, and UK research-chemical regulation under the Human Medicines Regulations 2012.
Every peptide profile is drafted from primary literature (PubMed and Elibrary.ru) and is checked against a 17-check editorial rubric before publication: mechanism must be attributable to a named published study, dosing must map to a published protocol, safety statements must reference the reported clinical or preclinical safety record, and every claim of regulatory status must be checked against the current MHRA / EMA position at the time of last review.
Where a named external clinical reviewer is retained (a UK-registered pharmacist or pharmacologist), their name, credential, and GMC/GPhC number will appear alongside the editorial team here and will populate the reviewedBy field of the schema.org markup emitted on every peptide page. That named-reviewer arrangement is actively being sought.
To flag an editorial correction, factual error, or missing citation, email the team via the address on the privacy policy. Corrections are made within one working week and the affected page's last reviewed date is bumped.
Editorial standards
Mechanism first
Every peptide page leads with the molecular mechanism. If a claim cannot be tied to a published mechanistic or clinical study, it does not appear.
Regulatory transparency
UK and EU regulatory status is stated explicitly on every page, including where the status differs across jurisdictions. No grey-area implications.
No therapeutic claims
Effects reported in research are research findings — not health benefits in humans. The distinction is maintained throughout.
Safety honesty
Where long-term human safety data is sparse — which is most peptides discussed here — the gap is named explicitly rather than glossed over.